RecruitingNCT05596578

Role of Intrapulmonary Lymph Nodes in Patients With NSCLC and Visceral Pleural Invasion


Sponsor

Luzerner Kantonsspital

Enrollment

958 participants

Start Date

Jan 1, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

Background: Lung cancer is the leading cause of cancer related death worldwide. More than 80% of all lung tumors are Non-Small Cell Lung Cancers (NSCLC). Lymph node staging has a prognostic value and is crucial to establish the optimal treatment strategy in individual patients. It remains unknown whether dissecting the intrapulmonary lymph nodes (stations 13 and 14) is necessary for accurate staging and prognostication. Although suggested by several guidelines, these peripheral lymph nodes are not routinely examined in clinical routine for several reasons. Moreover, the prognostic significance of the visceral pleural invasion is controversial. Some studies showed a negative impact on OS and DFS in patients with histologic proved visceral pleura invasion. The mechanism to explain this negative effect is not fully understood. Given that the visceral pleura is very rich in lymphatic vessels, with an intercommunicating "network" arranged over the lung surface and penetrating into the lung parenchyma to join the bronchial lymph vessels with drainage to the various hilar nodes, we assume that the worse OS and DFS observed in these patients could be explained with the presence of metastatic lymph nodes (Station 13-14) that are not routinely examined. Methods: This is a prospective, multicenter study based on ad-hoc created prospectively database. The incidence of N1 lymph node metastasis overall and the incidence of metastasis to the different lymph node stations (Hilar 10/11, Lobar 12, Sublobar 13/14) will be calculated by dividing the number of the respective events by the patient years separately. To investigate the association between visceral pleural invasion and the presence of metastatic lymph nodes univariate and multivariate logistic regression models will be fitted to the data. Discussion: The primary outcome is to investigate the incidence of N1 metastases (especially stations 12,13,14) and his relationship with visceral pleural invasion. The secondary outcomes is to evaluate the impact of N1 metastases and/or visceral pleural invasion on long-term outcomes (OS and DFS) along with incidence and pattern of recurrence. DFS is defined as the time of surgical intervention to tumor recurrence or death, and OS is defined as the time of surgical intervention to death


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study examines small lymph nodes found inside the lung tissue of patients who have had surgery for non-small cell lung cancer (NSCLC). Researchers want to understand whether these tiny lymph nodes contain cancer cells and how that affects cancer staging and treatment decisions. **You may be eligible if...** - You had surgery to remove part of your lung (lobectomy, bilobectomy, or segmentectomy) for NSCLC smaller than 3 cm - Lymph nodes from specific lung stations (12, 13, 14) were sampled during your surgery - The surgery achieved complete removal of the tumor (called R0 resection) **You may NOT be eligible if...** - You had a prior or simultaneous second lung cancer - Your surgery did not fully remove the tumor Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Kantonsspital Luzern

Lucerne, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05596578


Related Trials